Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Resistant Hypertension Clear all
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
View directory record Official record
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

NCT04519658
View directory record Official record
Conditions
Resistant Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Saraland, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

NCT04285554
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
iRF System Hepatic Denervation
Device
Lead sponsor
Metavention
Industry
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

NCT00819403
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
simvastatin, ezetimibe/simvastatin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jul 21, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional

Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension

NCT06543745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Frailty
Interventions
Low-Resistance Training
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 8:14 PM EDT
Recruiting Phase 4 Interventional

Impact GLP-1 Agonists Following Bariatric

NCT06132477
View directory record Official record
Conditions
Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
Interventions
GLP-1 receptor agonist
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 8:14 PM EDT
Withdrawn Phase 4 Interventional

The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

NCT02030314
View directory record Official record
Conditions
Resistant Hypertension in Kidney Transplant Patients
Interventions
Chlorthalidone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Jul 21, 2026, 8:14 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

NCT07180147
View directory record Official record
Conditions
Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome, Disability Physical, Hypertension, Metabolic Syndrome (MetS), Healthy Aging, Obesity &Amp; Overweight
Interventions
Not listed
Lead sponsor
Marymount University
Other
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Repeated Far Infrared Sauna Bathing in Adults With Obesity

NCT07158047
View directory record Official record
Conditions
Obesity (Disorder)
Interventions
Heat therapy
Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 21, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

NCT06343298
View directory record Official record
Conditions
Difficult to Control Hypertension
Interventions
MANP, Placebo Matched control
Drug · Other
Lead sponsor
E-Star BioTech, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Little Rock, Arkansas • Beverly Hills, California • Granada Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

8 Weeks of L-CIT Supplementation and LIRET on Vascular Function in Hypertensive Postmenopausal Women

NCT05227781
View directory record Official record
Conditions
Hypertension, Menopause
Interventions
L-Citrulline, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jul 21, 2026, 8:14 PM EDT
Not listed Not applicable Interventional

Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans

NCT03016351
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Aerobic Training, Resistance Training
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 4 Interventional

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

NCT00185094
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions
Olmesartan medoxomil, Losartan potassium, Atenolol
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2005 · Synced Jul 21, 2026, 8:14 PM EDT
Recruiting No phase listed Observational

Global Paradise System US Post Approval Study

NCT06297291
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Paradise Ultrasound Renal Denervation Treatment
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Sacramento, California • Santa Monica, California • Aurora, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 21, 2026, 8:14 PM EDT
Not yet recruiting Phase 2 Interventional

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT07473700
View directory record Official record
Conditions
Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions
TX000045
Drug
Lead sponsor
Tectonic Operating Company, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure

NCT00099476
View directory record Official record
Conditions
Hypertension
Interventions
Effects of dark chocolate
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 8:14 PM EDT
Completed No phase listed Observational

Methods for Measuring Insulin Sensitivity

NCT00001625
View directory record Official record
Conditions
Obesity, Hypertension, Diabetes-Mellitus, Non-Insulin Dependent
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

NCT05737940
View directory record Official record
Conditions
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

NCT05128929
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Hymecromone (H01), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 21, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 21, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

NCT03630211
View directory record Official record
Conditions
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
Drug · Radiation
Lead sponsor
Paul Szabolcs
Other
Eligibility
8 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 21, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

NCT00666172
View directory record Official record
Conditions
Atherosclerosis, Diabetes Mellitus, Obesity, Dyslipidemia, Hypertension
Interventions
Exercise, Weight Loss
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 8:14 PM EDT
Recruiting Phase 1 Interventional

Metabolic Effects of Angiotensin-(1-7)

NCT02646475
View directory record Official record
Conditions
Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 8:14 PM EDT